Softhale N.V. (Softhale) is a wholly owned subsidiary of invoX. It is a Belgian-based respiratory company focused on the development of pharmaceutical products delivered by their SMI device to the lungs.
Based in Diepenbeek, Belgium, Softhale N.V. is a pharmaceutical company specializing in the development of inhalable respiratory products.
Softhale is developing liquid-based, Soft Mist Inhaled (“SMI”) products with superior clinical performance based upon differentiated technology. A proprietary, propellant-free, purely mechanical device delivers medication to the lungs more effectively than other types of inhalers and in large markets including Asthma, COPD, and other lung indications.
On 22 March 2021, invoX entered into an agreement in relation to a 100% acquisition of Softhale.
invoX vision on Softhale
The following strategic significance is considered by the Board:
- Solidifies the Group’s leading position in the respiratory therapeutic area by offering the next general inhaler technology.
- Enhances the Group’s transformation from generics to innovation player by acquiring and fully controlling its own respiratory R&D capability.
- Accelerates the Group’s internationalization strategy by establishing a local hub in Europe as well as developing products with significant global market potential